XML 83 R46.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Collaboration Agreements (Other Collaborations) (Details) - USD ($) | 1 Months Ended | 12 Months Ended | 36 Months Ended
--- | --- | --- | ---
Oct. 31, 2008 | Dec. 29, 2017 | Dec. 30, 2016 | Jan. 01, 2016 | Dec. 29, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |
Maximum potential milestone payments |  | $ 1,900,000,000 |  |  | $ 1,900,000,000
Percentage of maximum potential milestone payments - clinical development |  | 9.00% |  |  | 9.00%
Percentage of maximum potential milestone payments - regulatory |  | 49.00% |  |  | 49.00%
Percentage of maximum potential milestone payments - commercial |  | 42.00% |  |  | 42.00%
GlaxoSmithKline [Member] |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |
Percent of royalty on net sales | 3.00% |  |  |  |
Collaborative Arrangement with Two Bristol-Myers Squibb Compound Utilized [Member] [Member] |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |
Percentage of costs |  | 33.33% |  |  |
Daiichi Sankyo [Member] |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |
Maximum amount eligible for development and regulatory milestones |  | $ 130,000,000 |  |  | $ 130,000,000
Revenue recognized, milestones |  | 0 | $ 15,000,000 | $ 0 |
Merck [Member] |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |
Maximum amount eligible for development and regulatory milestones |  | 231,000,000 |  |  | 231,000,000
Revenue recognized, milestones |  | 0 | 5,000,000 | 3,000,000 |
Maximum amount eligible for royalties on sales under collaborations agreement |  | 375,000,000 |  |  | 375,000,000
Collaborative Arrangement with BMS [Member] |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |
Maximum amount eligible for development and regulatory milestones |  | 240,000,000 |  |  | 240,000,000
Revenue recognized, milestones |  | 12,500,000 | 0 | 0 |
Maximum amount eligible for royalties on sales under collaborations agreement |  | 150,000,000 |  |  | 150,000,000
Sanofi [Member] |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |
Maximum amount eligible for development and regulatory milestones |  | $ 745,000,000.0 |  |  | 745,000,000.0
Revenue recognized, milestones |  |  | $ 0 | $ 0 | $ 0
Bristol Myers Squibb [Member] | Collaborative Arrangement with Two Bristol-Myers Squibb Compound Utilized [Member] [Member] |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |
Percentage of costs |  | 66.67% |  |  |

X
- Definition Maximum amount eligible for development and regulatory milestones under collaborations agreement. + References No definition available. + Details
Name: | exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones
Namespace Prefix: | exel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Arrangement, Share in Costs, Percentage + References No definition available. + Details
Name: | exel_CollaborativeArrangementShareinCostsPercentage
Namespace Prefix: | exel_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum Amount Eligible For Royalties on Sales Under Collaborations Agreement + References No definition available. + Details
Name: | exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement
Namespace Prefix: | exel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Maximum Potential Milestone Payments + References No definition available. + Details
Name: | exel_MaximumPotentialMilestonePayments
Namespace Prefix: | exel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Percent of royalty on net sale. + References No definition available. + Details
Name: | exel_PercentOfRoyaltyOnNetSale
Namespace Prefix: | exel_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of Maximum Potential Milestone Payments - Clinical Development + References No definition available. + Details
Name: | exel_PercentageofMaximumPotentialMilestonePaymentsClinicalDevelopment
Namespace Prefix: | exel_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of Maximum Potential Milestone Payments - Commercial + References No definition available. + Details
Name: | exel_PercentageofMaximumPotentialMilestonePaymentsCommercial
Namespace Prefix: | exel_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of Maximum Potential Milestone Payments - Regulatory + References No definition available. + Details
Name: | exel_PercentageofMaximumPotentialMilestonePaymentsRegulatory
Namespace Prefix: | exel_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_MajorCustomersAxis=exel_GlaxoSmithKlineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithDaiichiSankyoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithMerckMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithBMSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=exel_SanofiAventisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=exel_BristolMyersSquibbMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |